Interestingly, several large-scale retrospective trials have shown that GLP-1 mimetic therapies improve biomarkers of cardiovascular disease (CVD) and diminish the incidence of CVD events [11], [12], [13], [14]. This evidence concerns the gene GLP1R and cardiovascular disorder.